share_log

JP Morgan Maintains Underweight on Enanta Pharma, Lowers Price Target to $10

Benzinga ·  Aug 7 00:18  · Ratings

JP Morgan analyst Eric Joseph maintains Enanta Pharma (NASDAQ:ENTA) with a Underweight and lowers the price target from $11 to $10.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment